These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10566042)

  • 1. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
    [No Abstract]   [Full Text] [Related]  

  • 2. ISIS 2302. INXC ICAM1, Oligo-TCS.
    Drugs R D; 1999 Jan; 1(1):85-6. PubMed ID: 10565996
    [No Abstract]   [Full Text] [Related]  

  • 3. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide treatment of inflammatory bowel diseases.
    Yacyshyn BR
    Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
    [No Abstract]   [Full Text] [Related]  

  • 5. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT; Sitaraman SV
    Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
    Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alicaforsen therapy in inflammatory bowel disease.
    Barish CF
    Expert Opin Biol Ther; 2005 Oct; 5(10):1387-91. PubMed ID: 16197343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ridogrel. R 68070.
    Drugs R D; 1999 Mar; 1(3):270-2. PubMed ID: 10566044
    [No Abstract]   [Full Text] [Related]  

  • 10. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 11. Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel.
    Drugs R D; 1999 Mar; 1(3):258-61. PubMed ID: 10566040
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-10. Cytokine synthesis inhibitory factor, SCH 52000, rIL-10, rhIL-10.
    Drugs R D; 1999 Mar; 1(3):262-4. PubMed ID: 10566041
    [No Abstract]   [Full Text] [Related]  

  • 13. GEM 132. Gene expression modulation 132.
    Drugs R D; 1999 Nov; 2(5):313-4. PubMed ID: 10728469
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
    van Deventer SJ; Tami JA; Wedel MK
    Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
    Kahan BD; Stepkowski S; Kilic M; Katz SM; Van Buren CT; Welsh MS; Tami JA; Shanahan WR
    Transplantation; 2004 Sep; 78(6):858-63. PubMed ID: 15385805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E 3040.
    Drugs R D; 1999 Mar; 1(3):256-7. PubMed ID: 10566039
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acemannan. CARN 1000, CARN 750, polymannoacetate, Aliminase, Alovex, Carrisyn.
    Drugs R D; 1999 Mar; 1(3):251-2. PubMed ID: 10566037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.